[Frontiers In Bioscience, Elite, 10, 334-343, March 1, 2018]

Daily subcutaneous testosterone for management of testosterone deficiency

Nasimeh Yazdani1, Stacy Matthews Branch2

1Seaside Medical Practice, 2001 Santa Monica Blvd, Suite 765W, Santa Monica, CA 90404, 2Djehuty Biomed Consulting, 106 Rugged Dr., Red Oak, TX 75154


1. Abstract
2. Introduction
2.1. Definition of Testosterone Deficiency
2.2. Diagnosing Testosterone Deficiency
2.3. Treatment Approaches for Testosterone Deficiency
3. Methods
3.1 Statistical Analysis
4. Results and Discussion
5. Conclusion
6. Acknowledgements
7. References


Testosterone deficiency (TD) is a public health concern, a predictor of metabolic syndrome, and is associated with an increased all-cause and cardiovascular mortality. Testosterone deficiency in men is treated by a variety of methods including injectable testosterone compounds, patches, gels, pellets, and oral preparations. The use of testosterone alone has been linked to various adverse effects including, infertility, testicular atrophy, erythropoiesis, and gynecomastia. To determine the effectiveness of therapy using the Daily Subcutaneous Testosterone (DST) method in combination with human chorionic gonadotropin (hCG) and an aromatase inhibitor (anastrozole), a retrospective analysis was conducted of men diagnosed and treated for TD. Changes in testosterone, estradiol, sex hormone binding globulin (SHBG), luteinizing hormone (LH), follicle stimulating hormone (FSH), dihydrotestosterone (DHT), dehydroepiandrosterone sulfate (DHEA-S), prostate-specific antigen (PSA), pregnenolone, and hemoglobin were determined. There was a significant increase in total testosterone, free serum testosterone, and direct free testosterone in the testosterone treated patients. There was a significant increase in total and free testosterone levels with the DST method combined with hCG and anastrozole, suggesting that DST therapy is a viable option to restore testosterone levels in men.


1. V Zarotsky, M -Y Huang, W Carman, A Morgentaler, P K Singhal, D Coffin and T H Jones: Systematic Literature Review of the Epidemiology of Nongenetic Forms of Hypogonadism in Adult Males. Journal of Hormones, 2014, 17 (2014)

2. J A McBride, C C Carson, R M Coward. Testosterone deficiency in the aging male: Ther Adv Urol. 8(1), 47-60 2016

3. S A Burnett-Bowie, E A McKay, H Lee and B Z Leder: . J Clin Endocrinol Metab, 94(12), 4785-92 (2009)
DOI: 10.1210/jc.2009-0739
PMid:19820017 PMCid:PMC2795655

4. G Corona, G Rastrelli, M Monami, A Guay, J Buvat, A Sforza, G Forti, E Mannucci and M Maggi: Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study Eur J Endocrinol, 165(5), 687-701 (2011)

5. G Corona G, M Monami, G Rastrelli, A Aversa, A Sforza, A Lenzi, et al.: Type 2 diabetes mellitus and testosterone: a meta-analysis study. International journal of andrology. 2011;34(6 Pt 1):528-40.

6. R Blaya, L D Thomaz, F Guilhermano, O Paludo Ade, L Rhoden, G Halmenschlager and E L Rhoden: Total testosterone levels are correlated to metabolic syndrome components. Aging Male, 19(2), 85-9 (2016)
DOI: 10.3109/13685538.2016.1154523

7. G R Cunningham: Testosterone and metabolic syndrome. Asian J Androl, 17(2), 192-6 (2015)
DOI: 10.4103/1008-682X.148068
PMid:25652634 PMCid:PMC4650473

8. A Traish: Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return? Investig Clin Urol, 57(6), 384-400 (2016)

9. V A Giagulli, V Triggiani, M D Carbone, G Corona, E Tafaro, B Licchelli, E Guastamacchia: The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism. J Sex Med. 8(12), 3471-8 (2011)
DOI: 10.1111/j.1743-6109.2011.02497.x

10. D A Paduch, R e Brannigan, E F Fuchs, E D Kim, J L Marmar and J I Sandlow: The Laboratory Diagnosis of Testosterone Deficiency In: The American Urological Association, Inc , (2013)

11. A Vermeulen, L Verdonck and J M Kaufman: A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab, 84(10), 3666-72 (1999)
DOI: 10.1210/jcem.84.10.6079

12. M Zitzmann, S Faber, E Nieschlag: Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab, 91(11), 4335-43 (2006)
DOI: 10.1210/jc.2006-0401

13. C Wang, E Nieschlag, R Swerdloff, H M Behre, W J Hellstrom, L J Gooren, J M Kaufman, J J Legros, B Lunenfeld, A Morales, J E Morley, C Schulman, I M Thompson, W Weidner and F C Wu: Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol, 159(5), 507-14 (2008)
DOI: 10.1530/EJE-08-0601
PMid:18955511 PMCid:PMC2754376

14. A Morgentaler, M Zitzmann, A M Traish, A W Fox, T H Jones, M Maggi, S Arver, A Aversa, J C Chan, A S Dobs, G I Hackett, W J Hellstrom, P Lim, B Lunenfeld, G Mskhalaya, C C Schulman and L O Torres: Fundamental Concepts Regarding Testosterone Deficiency and Treatment: International Expert Consensus Resolutions. Mayo Clin Proc, 91(7), 881-96 (2016)
DOI: 10.1016/j.mayocp.2016.04.007

15. B S Hong and T Y Ahn: Recent trends in the treatment of testosterone deficiency syndrome. Int J Urol, 14(11), 981-5 (2007)
DOI: 10.1111/j.1442-2042.2007.01882.x

16. G Corona, E Maseroli and M Maggi: Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opin Pharmacother, 15(13), 1903-26 (2014)
DOI: 10.1517/14656566.2014.944896

17. T Middleton, L Turner, C Fennell, S Savkovic, V Jayadev, A J Conway and D J Handelsman: Complications of injectable testosterone undecanoate in routine clinical practice. Eur J Endocrinol, 172(5), 511-7 (2015)
DOI: 10.1530/EJE-14-0891

18. M A Mackey, A J Conway and D J Handelsman: Tolerability of intramuscular injections of testosterone ester in oil vehicle. Hum Reprod, 10(4), 862-5 (1995)
DOI: 10.1093/oxfordjournals.humrep.a136051

19. R Nakazawa, K Baba, M Nakano, T Katabami, N Saito, T Takahashi and T Iwamoto: Hormone profiles after intramuscular injection of testosterone enanthate in patients with hypogonadism. Endocr J, 53(3), 305-10 (2006)
DOI: 10.1507/endocrj.K05-069

20. A A Yassin and M Haffejee: Testosterone depot injection in male hypogonadism: a critical appraisal. Clin Interv Aging, 2(4), 577-90 (2007)

21. J D Scott, P R Wolfe, P Anderson, G R Cohan and A Scarsella: Prospective study of topical testosterone gel (AndroGel) versus intramuscular testosterone in testosterone-deficient HIV-infected men. HIV Clin Trials, 8(6), 412-20 (2007)
DOI: 10.1310/hct0806-412

22. J J Shoskes, M K Wilson and M L Spinner: Pharmacology of testosterone replacement therapy preparations. Transl Androl Urol, 5(6), 834-843 (2016)
DOI: 10.21037/tau.2016.08.07
DOI: 10.21037/tau.2016.07.10
PMid:28078214 PMCid:PMC5182226

23. H R Nankin: Hormone kinetics after intramuscular testosterone cypionate. Fertil Steril, 47(6), 1004-9 (1987)
DOI: 10.1016/S0015-0282(16)59237-1

24. J Kaminetsky, J S Jaffe and R S Swerdloff: Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study. Sex Med, 3(4), 269-79 (2015)
DOI: 10.1002/sm2.80
PMid:26797061 PMCid:PMC4721027

25. D I Spratt, I Stewart, C Savage, W Craig, N P Spack, D W Chandler, et al: Subcutaneous Injection of Testosterone is an Effective and Preferred Alternative to Intramuscular Injection: Demonstration in Female-to-Male Transgender Patients. The Journal of clinical endocrinology and metabolism, 1-9 (2017)

26. E L Rhoden, A Morgentaler: Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy. Int J Impot Res. 18(2):201-5 (2006)

27. D Muram, T Melby, E Alles Kingshill: Skin reactions in a phase 3 study of a testosterone topical solution applied to the axilla in hypogonadal men. Curr Med Res Opin. 28(5), 761-6 (2012)
DOI: 10.1185/03007995.2012.681034

28. E D Grober: Testosterone deficiency and replacement: Myths and realities Can Urol Assoc J, 8(7-8 Suppl 5), S145-7 (2014)

29. J Hassan and J Barkin: Testosterone deficiency syndrome: benefits, risks, and realities associated with testosterone replacement therapy. Can J Urol, 23(Suppl 1), 20-30 (2016)

30. S O Kim, K H Ryu, I S Hwang, S I Jung, K J Oh and K Park: Penile Growth in Response to Human Chorionic Gonadotropin (hCG) Treatment in Patients with Idiopathic Hypogonadotrophic Hypogonadism. Chonnam Med J, 47(1), 39-42 (2011)
DOI: 10.4068/cmj.2011.47.1.39
PMid:22111055 PMCid:PMC3214853

31. E P Wenker, J M Dupree, G M Langille, J Kovac, R Ramasamy, D Lamb, J N Mills and L I Lipshultz: The Use of HCG-Based Combination Therapy for Recovery of Spermatogenesis after Testosterone Use. J Sex Med, 12(6), 1334-7 (2015)
DOI: 10.1111/jsm.12890

32. N Sato, T Hasegawa, Y Hasegawa, O Arisaka, K Ozono, S Amemiya, T Kikuchi, H Tanaka, S Harada, I Miyata and T Tanaka: Treatment situation of male hypogonadotropic hypogonadism in pediatrics and proposal of testosterone and gonadotropins replacement therapy protocols. Clin Pediatr Endocrinol, 24(2), 37-49 (2015)
DOI: 10.1297/cpe.24.37
PMid:26019400 PMCid:PMC4436555

33. T C Hsieh, A W Pastuszak, K Hwang and L I Lipshultz: Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy J Urol, 189(2), 647-50 (2013)

34. A S Burris, H W Rodbard, S J Winters and R J Sherins: Gonadotropin therapy in men with isolated hypogonadotropic hypogonadism: the response to human chorionic gonadotropin is predicted by initial testicular size J Clin Endocrinol Metab, 66(6), 1144-51 (1988)

35. C W Mechlin, J Frankel and A McCullough: Coadministration of anastrozole sustains therapeutic testosterone levels in hypogonadal men undergoing testosterone pellet insertion J Sex Med, 11(1), 254-61 (2014)

36. R S Tan, K R Cook and W G Reilly: High estrogen in men after injectable testosterone therapy: the low T experience Am J Mens Health, 9(3), 229-34 (2015)

37. W de Ronde and F H de Jong: Aromatase inhibitors in men: effects and therapeutic options. Reprod Biol Endocrinol, 9, 93 (2011)

38. S A Burnett-Bowie, K C Roupenian, M E Dere, H Lee and B Z Leder: Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf), 70(1), 116-23 (2009)
DOI: 10.1111/j.1365-2265.2008.03327.x

39. J K Amory, M A Bush, H Zhi, R B Caricofe, A M Matsumoto, R S Swerdloff, C Wang and R V Clark: Oral testosterone with and without concomitant inhibition of 5alpha-reductase by dutasteride in hypogonadal men for 28 days. J Urol, 185(2), 626-32 (2011)
DOI: 10.1016/j.juro.2010.09.089
PMid:21168874 PMCid:PMC4267472

40. N Wada, K Hashizume, S Matsumoto and H Kakizaki: Dutasteride improves bone mineral density in male patients with lower urinary tract symptoms and prostatic enlargement: a preliminary study. Aging Male, 19(1), 12-4 (2016)
DOI: 10.3109/13685538.2015.1072155

41. Y H Chong, M W Pankhurst and I S McLennan: The Daily Profiles of Circulating AMH and INSL3 in Men are Distinct from the Other Testicular Hormones, Inhibin B and Testosterone. PLoS One, 10(7), e0133637 (2015)
DOI: 10.1371/journal.pone.0133637
PMid:26192622 PMCid:PMC4507845

42. S G Korenman, H Wilson and M B Lipsett: Testosterone production rates in normal adults. J Clin Invest, 42, 1753-60 (1963)
DOI: 10.1172/JCI104860
PMid:14083165 PMCid:PMC289458

43. H Vierhapper, P Nowotny and W Waldhausl: Determination of testosterone production rates in men and women using stable isotope/dilution and mass spectrometry. J Clin Endocrinol Metab, 82(5), 1492-6 (1997)
DOI: 10.1210/jc.82.5.1492
DOI: 10.1210/jcem.82.5.3958

44. C Wang, D H Catlin, B Starcevic, A Leung, E DiStefano, G Lucas, L Hull and R S Swerdloff: Testosterone metabolic clearance and production rates determined by stable isotope dilution/tandem mass spectrometry in normal men: influence of ethnicity and age. J Clin Endocrinol Metab, 89(6), 2936-41 (2004)
DOI: 10.1210/jc.2003-031802

45. A W Pastuszak, L P Gomez, J M Scovell, M Khera, D J Lamb and L I Lipshultz: Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen. Sex Med, 3(3), 165-73 (2015)
DOI: 10.1002/sm2.76
PMid:26468380 PMCid:PMC4599554

46. B Z Leder, J L Rohrer, S D Rubin, J Gallo and C Longcope: Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocrinol Metab, 89(3), 1174-80 (2004)

47. Healthcare UoI. University of Iowa Laboratory Services Handbook Iowa City, Iowa: University of Iowa.s; (updated 10/6/2016). Available from: https://www.healthcare.uiowa.edu/path_handbook/.

48. G A Brown, M D Vukovich, R L Sharp, T A Reifenrath, K A Parsons and D S King: Effect of oral DHEA on serum testosterone and adaptations to resistance training in young men. J Appl Physiol (1985), 87(6), 2274-83 (1999)

49. Medicine USNLo DHEA-sulfate test Bethesda, MD: U S National Library of Medicine (updated 10/5/2016) Available from: https://medlineplus gov/ency/article/003717 htm

50. G Bartsch, R S Rittmaster and H Klocker: Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol, 19(6), 413-25 (2002)

51. N F Agamia, T Abou Youssif, A El-Hadidy and A El-Abd: Benign prostatic hyperplasia, metabolic syndrome and androgenic alopecia: Is there a possible relationship? Arab J Urol, 14(2), 157-62 (2016)

52. J Gore and J Rajfer: Rising PSA during Testosterone Replacement Therapy. Rev Urol, 6(Suppl 6), S41-3 (2004)

53. F M Debruyne, H M Behre, C G Roehrborn, M Maggi, F C Wu, F H Schroder, T H Jones, H Porst, G Hackett, O A Wheaton, A Martin-Morales, E Meuleman, G R Cunningham, H A Divan and R C Rosen: Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men. BJU Int (2016)

54. I J Osuji, E Vera-Bolanos, T J Carmody and E S Brown: Pregnenolone for cognition and mood in dual diagnosis patients. Psychiatry Res, 178(2), 309-12 (2010)

Key Words: Daily Subcutaneous Testosterone Method, Testosterone, Serum Free Testosterone, Testosterone Deficiency, human chorionic gonadotropin, aromatase inhibitor

Send correspondence to: Nasimeh Yazdani, Seaside Medical Practice, 2001 Santa Monica Blvd, Suite 765W, Santa Monica, CA 90404, Tel: 310-393-5000 Fax: 310-393-5007, E-mail: dryazdani@seasidemedicalpractice.com